Cosmo N.V. (SWX: CMHC)
Health Care · Pharmaceuticals · IE
CHF55.00
-0.90% today · -16.8% 1Y
Cosmo N.V. (SWX: CMHC) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.12B and employs 3,245 people.
Over the last twelve months the share price has lost 16.8%, trading between 49.00 and 129.40.
Tweenvest scores Cosmo N.V. across four factors: quality 67/100, value 71/100, growth 14/100, dividend 68/100. Its strongest factor is value.
CMHC price history
Key figures
- Market cap
- $1.12B
- Revenue (TTM)
- $117.32M
- P/E
- -152.23
- EPS
- -0.35
- Dividend yield
- 3.44%
- Beta (5Y)
- 1.48
- 52-week high
- CHF129.40
- 52-week low
- CHF49.00
- Avg volume (3M)
- —
- Shares outstanding
- 17.19M
- Employees
- 3,245
- Next earnings
- —
About Cosmo N.V.
Cosmo NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.
- ISIN
- NL0011832936
- Founded
- 1997
- Listed since
- Mar 12, 2007
- Exchange
- SIX Swiss Exchange
- Currency
- CHF
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Lotus Pharmaceutical Co., Ltd.TWSE: 1795 | $1.16B | NT$141.50 | -9.29% |
| North China Pharmaceutical Company.LtdSHSE: 600812 | $1.15B | CN¥4.46 | -0.89% |
| Tianjin Ringpu Bio-Technology Co.,Ltd.SZSE: 300119 | $1.13B | CN¥16.54 | -0.42% |
| MedinCell S.A.ENXTPA: MEDCL | $1.13B | €28.48 | -1.18% |
| Viyash Scientific LimitedBSE: 512529 | $1.11B | Rs236.25 | -7.39% |
| Vetoquinol SAENXTPA: VETO | $1.10B | €86.30 | -0.12% |
| Guilin Sanjin Pharmaceutical Co., Ltd.SZSE: 002275 | $1.10B | CN¥12.46 | -3.56% |
| ST Pharm Co.,Ltd.KOSDAQ: A237690 | $1.10B | ₩70,200.00 | -1.13% |